NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $391,000 | -65.9% | 19,562 | -69.0% | 0.00% | -81.8% |
| Q3 2019 | $1,148,000 | -19.0% | 63,036 | +58.3% | 0.01% | 0.0% |
| Q2 2019 | $1,417,000 | +1.2% | 39,828 | -4.4% | 0.01% | 0.0% |
| Q1 2019 | $1,400,000 | -62.1% | 41,677 | -62.9% | 0.01% | -35.3% |
| Q4 2018 | $3,690,000 | +26.9% | 112,274 | +135.4% | 0.02% | -32.0% |
| Q3 2018 | $2,907,000 | +66.3% | 47,689 | +33.2% | 0.02% | +66.7% |
| Q2 2018 | $1,748,000 | -44.9% | 35,807 | +20.0% | 0.02% | -55.9% |
| Q1 2018 | $3,170,000 | – | 29,831 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |